Aldeyra Therapeutics, Inc. Logo

Aldeyra Therapeutics, Inc.

Develops medications for immune-mediated ocular and systemic diseases.

ALDX | US

Overview

Corporate Details

ISIN(s):
US01438T1060
LEI:
Country:
United States of America
Address:
131 HARTWELL AVENUE, 2421 LEXINGTON

Description

Aldeyra Therapeutics is a biotechnology company developing medications for immune-mediated diseases. The company's therapeutic approach involves modulating immunological systems rather than inhibiting or activating single protein targets, with the goal of optimizing multiple pathways while minimizing toxicity. Its portfolio of product candidates targets inflammatory cells associated with both ocular and systemic ailments. Aldeyra has investigational therapies in late-stage clinical development for conditions such as dry eye disease and allergic conjunctivitis, aiming to address medical needs not adequately met by existing treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-12 22:36
4
English 7.2 KB
2025-06-12 22:30
4
English 7.3 KB
2025-06-12 22:29
4
English 7.4 KB
2025-06-12 22:27
4
English 7.3 KB
2025-06-12 22:27
4
English 7.5 KB
2025-06-12 22:21
4
English 7.4 KB
2025-06-11 22:01
8-K
English 58.3 KB
2025-05-14 23:13
10-Q
English 2.3 MB
2025-05-06 13:01
8-K
English 2.3 MB
2025-04-25 22:28
ARS
English 13.0 MB
2025-04-25 22:25
DEFA14A
English 937.1 KB
2025-04-25 22:19
DEF 14A
English 2.1 MB
2025-04-18 22:41
4
English 7.0 KB
2025-04-18 22:21
3
English 6.1 KB
2025-04-17 22:01
CURRENT REPORT
English 111.4 KB

Automate Your Workflow. Get a real-time feed of all Aldeyra Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aldeyra Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aldeyra Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.